Roche Could Lose $1 Billion on Revoked Avastin Breast Cancer Use (RHHBY)

Roche Holding AG’s RHHBY top selling cancer drug Avastin may lose $1 billion in annual revenue if U.S. regulators revoke approval of the drug for use in breast cancer after a panel voted 12-1 yesterday to rescind it in Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.